Quince Ends Development of Lead Drug Candidate; Shares Slide

Dow Jones01-30

By Elias Schisgall

Quince Therapeutics will end the development of its lead asset, a treatment for the neurodegenerative disorder ataxia-telangiectasia, after a pivotal Phase 3 trial failed to meet its expected outcomes.

The drug candidate, dexamethasone sodium phosphate encapsulated in autologous erythrocytes, or eDSP, did not achieve statistical significance its primary and key secondary endpoints, the biotechnology company said Thursday afternoon.

Shares for Quince nosedived to 27 cents a share ahead of the market close. The stock opened at $3.18 Thursday.

Quince said cancelling the program would preserve cash and allow the company to explore available alternatives.

"We express our compassion and hope for future therapeutic options to the A-T community," Chief Executive Officer and Chief Medical Officer Dirk Thye said. "We have tremendous gratitude toward the patients, their families, academic investigators and study sites, as well as all Quince employees, who worked so diligently over many years on this program."

Quince released safety data for eDSP on Wednesday afternoon. It said Thursday that the drug was generally well-tolerated without clinically meaningful safety concerns.

Write to Elias Schisgall at elias.schisgall@wsj.com

(END) Dow Jones Newswires

January 29, 2026 15:52 ET (20:52 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2607105682?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-30 04:52","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2607105682","market":"nz","top_or_hot":-1,"title":"Quince Ends Development of Lead Drug Candidate; Shares Slide","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Elias Schisgall \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Quince <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> will end the development of its lead asset, a treatment for the neurodegenerative disorder ataxia-telangiectasia, after a pivotal Phase 3 trial failed to meet its expected outcomes. \n</p>\n<p>\n  The drug candidate, dexamethasone sodium phosphate encapsulated in autologous erythrocytes, or eDSP, did not achieve statistical significance its primary and key secondary endpoints, the biotechnology company said Thursday afternoon. \n</p>\n<p>\n  Shares for Quince nosedived to 27 cents a share ahead of the market close. The stock opened at $3.18 Thursday. \n</p>\n<p>\n  Quince said cancelling the program would preserve cash and allow the company to explore available alternatives. \n</p>\n<p>\n  \"We express our compassion and hope for future therapeutic options to the A-T community,\" Chief Executive Officer and Chief Medical Officer Dirk Thye said. \"We have tremendous gratitude toward the patients, their families, academic investigators and study sites, as well as all Quince employees, who worked so diligently over many years on this program.\" \n</p>\n<p>\n  Quince released safety data for eDSP on Wednesday afternoon. It said Thursday that the drug was generally well-tolerated without clinically meaningful safety concerns. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Elias Schisgall at elias.schisgall@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 29, 2026 15:52 ET (20:52 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Quince Ends Development of Lead Drug Candidate; Shares Slide</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nQuince Ends Development of Lead Drug Candidate; Shares Slide\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-01-30 04:52</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Elias Schisgall \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Quince <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> will end the development of its lead asset, a treatment for the neurodegenerative disorder ataxia-telangiectasia, after a pivotal Phase 3 trial failed to meet its expected outcomes. \n</p>\n<p>\n  The drug candidate, dexamethasone sodium phosphate encapsulated in autologous erythrocytes, or eDSP, did not achieve statistical significance its primary and key secondary endpoints, the biotechnology company said Thursday afternoon. \n</p>\n<p>\n  Shares for Quince nosedived to 27 cents a share ahead of the market close. The stock opened at $3.18 Thursday. \n</p>\n<p>\n  Quince said cancelling the program would preserve cash and allow the company to explore available alternatives. \n</p>\n<p>\n  \"We express our compassion and hope for future therapeutic options to the A-T community,\" Chief Executive Officer and Chief Medical Officer Dirk Thye said. \"We have tremendous gratitude toward the patients, their families, academic investigators and study sites, as well as all Quince employees, who worked so diligently over many years on this program.\" \n</p>\n<p>\n  Quince released safety data for eDSP on Wednesday afternoon. It said Thursday that the drug was generally well-tolerated without clinically meaningful safety concerns. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Elias Schisgall at elias.schisgall@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 29, 2026 15:52 ET (20:52 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2607105682","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2607105682","pubTimestamp":1769719920,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Quince Therapeutics will end the development of its lead asset, a treatment for the neurodegenerative disorder ataxia-telangiectasia, after a pivotal Phase 3 trial failed to meet its expected outcomes.The drug candidate, dexamethasone sodium phosphate encapsulated in autologous erythrocytes, or eDSP, did not achieve statistical significance its primary and key secondary endpoints, the biotechnology company said Thursday afternoon.Shares for Quince nosedived to 27 cents a share ahead of the market close. The stock opened at $3.18 Thursday.Quince said cancelling the program would preserve cash and allow the company to explore available alternatives.\"We express our compassion and hope for future therapeutic options to the A-T community,\" Chief Executive Officer and Chief Medical Officer Dirk Thye said. \"We have tremendous gratitude toward the patients, their families, academic investigators and study sites, as well as all Quince employees, who worked so diligently over many years on this ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","QNCX":"Quince Therapeutics, Inc."},"translate_title":"Quince结束主要候选药物的开发；股票下滑","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"QNCX":0.9},"content_text":"By Elias Schisgall \n\n\n \n\n\n  Quince Therapeutics will end the development of its lead asset, a treatment for the neurodegenerative disorder ataxia-telangiectasia, after a pivotal Phase 3 trial failed to meet its expected outcomes. \n\n\n  The drug candidate, dexamethasone sodium phosphate encapsulated in autologous erythrocytes, or eDSP, did not achieve statistical significance its primary and key secondary endpoints, the biotechnology company said Thursday afternoon. \n\n\n  Shares for Quince nosedived to 27 cents a share ahead of the market close. The stock opened at $3.18 Thursday. \n\n\n  Quince said cancelling the program would preserve cash and allow the company to explore available alternatives. \n\n\n  \"We express our compassion and hope for future therapeutic options to the A-T community,\" Chief Executive Officer and Chief Medical Officer Dirk Thye said. \"We have tremendous gratitude toward the patients, their families, academic investigators and study sites, as well as all Quince employees, who worked so diligently over many years on this program.\" \n\n\n  Quince released safety data for eDSP on Wednesday afternoon. It said Thursday that the drug was generally well-tolerated without clinically meaningful safety concerns. \n\n\n \n\n\n  Write to Elias Schisgall at elias.schisgall@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 29, 2026 15:52 ET (20:52 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2607105682","isCrawlerRequest":true}